Please login to the form below

Not currently logged in
Email:
Password:

CINV

This page shows the latest CINV news and features for those working in and with pharma, biotech and healthcare.

Rare disease therapies head the ‘class of 2015’

Rare disease therapies head the ‘class of 2015’

Relypsa. USA. rolapitant. Varubi. chemotherapy-induced nausea and vomiting (CINV). neurokinin-1 receptor antagonist.

Latest news

  • Merck plans expanded filing for Emend this year Merck plans expanded filing for Emend this year

    Merck &Co's nausea and vomiting therapy Emend is effective in preventing chemotherapy-induced nausea and vomiting (CINV) even when given as a single dose, says a new study. ... Generics aside, competition is building in the CINV sector. Last October the

  • GSK files NDA in the US

    FDA). The drug performed well during trials, with results showing that it significantly reduced the number of patients who experienced CINV. ... The company said that 40 to 50 per cent of patients still succumb to breakthrough CINV despite being on

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

The Exhibition Hall: Past, Present and Future
As I sit here at another pharma conference, I start to reflect on how they have changed over the years....
Success breeds success
This week we received the exciting news that we have been shortlisted for the Times Business Awards 2019, Tunbridge Wells in the 'Best Business 1-25 Employees' category....
Turning learning into action: The challenge of behaviour change
...

Infographics